Avinger Announces Participation in Cowen and Company 38th Annual Health Care Conference
05. März 2018 08:00 ET
|
Avinger, Inc.
REDWOOD CITY, Calif, March 05, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that the...
Avinger Regains Compliance with Nasdaq Listing Requirements
02. März 2018 08:00 ET
|
Avinger, Inc.
REDWOOD CITY, Calif., March 02, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced it has...
OPS Code Established for Peripheral Vascular OCT Imaging in Germany
20. Februar 2018 08:00 ET
|
Avinger, Inc.
REDWOOD CITY, Calif., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced that the German...
Avinger Announces Closing of $18 Million Underwritten Public Offering
16. Februar 2018 13:30 ET
|
Avinger, Inc.
REDWOOD CITY, Calif., Feb. 16, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced the closing of...
Avinger Announces Pricing of $18 Million Underwritten Public Offering
14. Februar 2018 08:30 ET
|
Avinger, Inc.
REDWOOD CITY, Calif., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced the pricing of...
Avinger’s Next Generation Pantheris Featured in Live Case Transmission at Leipzig Interventional Course 2018
02. Februar 2018 08:00 ET
|
Avinger, Inc.
REDWOOD CITY, Calif., Feb. 02, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced that its next...
Avinger Announces Reverse Stock Split
30. Januar 2018 16:45 ET
|
Avinger, Inc.
REDWOOD CITY, Calif., Jan. 30, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that the...
Avinger Granted Continued Listing Decision From Nasdaq
19. Januar 2018 08:00 ET
|
Avinger, Inc.
REDWOOD CITY, Calif., Jan. 19, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced today that the...
Avinger Announces Treatment of First Patients Globally With Next Generation Pantheris
03. Januar 2018 08:30 ET
|
Avinger, Inc.
REDWOOD CITY, Calif., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced that Arne Schwindt,...
Avinger Announces 510(k) Filing of Next Generation Pantheris Device
21. Dezember 2017 08:30 ET
|
Avinger, Inc.
REDWOOD CITY, Calif., Dec. 21, 2017 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced the Company submitted...